C3G increases the proportion of Treg cells in MNCs by decreasing the proportion of CD38+ NK cells, thereby increasing IL-10 secretion, decreasing IL-6 and IFN-γ levels, and achieving therapeutic effects on RA. Here, IL6 is linked to rheumatoid arthritis.